BioCentury | Mar 27, 2019
Translation in Brief

A mitochondrial shield from cell death

...low counts. In addition, cells with higher mitochondrial counts required higher levels of BAX and BAK1...
...trial to solid and hematological cancers. While no companies have disclosed programs targeting BAX or BAK1...
...mitochondrial proteins BCL-2 and Bcl-XL that are also involved in regulating apoptosis. Targets: BAK1 - BCL2-antagonist/killer 1...
BioCentury | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

...a lysine in MCL1 that disrupts interactions between the cancer target and the proapoptotic protein BAK1...
...Scripps Research Institute, La Jolla, Calif. Vividion Therapeutics Inc., San Diego, Calif. Targets BAK1 - BCL2-antagonist/killer 1...
BioCentury | Nov 11, 2016
Tools & Techniques

Chemistry beyond candidates

...of anti-apoptotic protein MCL1 (green) , which blocked its interaction with other proteins, such as BAK1...
...undergo metal-free silylation (green box) or transfer-hydrogenation reactions at ambient temperature and pressure. BAK1 - BCL2-antagonist/killer 1...
...Uppsala University, Uppsala, Sweden Wellcome Trust Centre for Cell-Matrix Research, Manchester, U.K. Targets BAK1 - BCL2-antagonist/killer 1...
BioCentury | Jul 27, 2015
Company News

Sun Pharma, Sun Pharmaceutical deal

SPARC granted Sun U.S. rights to Xelpros eye drops, a benzalkonium chloride (BAK)-free formulation of the glaucoma drug latanoprost that uses Swollen Micelle Microemulsion (SMM) technology. Xelpros is under FDA review. SPARC will receive $3...
BioCentury | Jan 16, 2014
Targets & Mechanisms

Putting a lid on cancer cell proteasomes

...ligase, leading to stabilization of the p53 tumor suppressor and the proapoptotic proteins BCL2-antagonist/killer 1 ( BAK1...
BioCentury | Feb 28, 2013
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1...
BioCentury | Feb 14, 2013
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1...
BioCentury | Mar 17, 2011
Targets & Mechanisms

MCL1's resistance story

...a proapoptotic protein member of the BCL2 family such as BCL2-associated X protein (BAX) or BCL2-antagonist/killer 1 (BAK1)...
BioCentury | Feb 7, 2011
Clinical News

BAK-free DuoTrav travoprost/timolol regulatory update

Alcon disclosed in its 4Q10 earnings that it submitted an MAA to the European Medicines Agency (EMA) for a benzalkonium chloride (BAK)-free formulation of DuoTrav travoprost/timolol ophthalmic solution to reduce elevated intraocular pressure (IOP) in...
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Neurology

...Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) BCL2-associated X protein (BAX); BCL2-antagonist/killer 1 (BAK1)...
...familial ALS. In a mouse model of familial ALS, CNS-specific deletion of both BAX and BAK1...
Items per page:
1 - 10 of 29